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A group of inactivators of cysteinyl proteinases which function by covalent bond formation have been examined for their ability to inhibit the 
development of Plusmodiutn falciparum within red blood cells. The most effective of these caused inactivation of the parasite near 10e8 M concentra- 
tion. The range of inhibitory action varied with peptide structure in a manner characteristic of affinity labels for proteinases uggesting that the 
target of inhibition was an unidentified proteinase, probably of the cysteinyl type, but different from cathepsins B and L. 
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1. INTRODUCTION 
The study of plasmodial proteinases is currently 
under investigation in connection with various features 
of the life-cycle of the parasite [l-5] including 
erythrocyte invasion [ 11, intra-erythrocytic events such 
as hemoglobin digestion [2,4,5] and merozoite matura- 
tion [3]. The use of specific inhibitors to obtain 
evidence for the physiological role of these proteinases 
and conceivably to lead to therapeutic applications is a 
logical extension of these studies. The success of this ap- 
proach will depend on the specificity of the inhibitors 
since host cells employ similar proteinases for useful 
functions. Considerable progress has been made in the 
development of inactivators that function by affinity 
labelling, using peptide sequences which satisfy the 
specificity of a target proteinase but are also capable of 
forming a covalent bond at the active center. Peptide 
derivatives that irreversibly inactivate serine and cys- 
teinyl proteinases include peptidyl chloromethanes [6], 
fluoromethanes [7- 131, diazomethyl ketones [ 14- 181 
and peptidyl methyl sulfonium salts [19,20]. Variation 
in the peptidyl portion may provide selectivity of inac- 
tivation among closely related proteinases. This may be 
difficult to achieve within a common mechanistic fami- 
ly, but exploration of inhibitor structures has revealed 
useful enzyme differences, including topographical 
variations [17,18]. 
We found previously that certain peptidylfluoro- 
methanes, and in particular, one containing the novel 
amino acid imidazolylnorvaline, ImNva [ 121 are able to 
lyse the infectious but not the non-infectious forms of 
African and South American trypanosomes in vitro 
(Ashall, Angliker and Shaw, in preparation). We subse- 
quently examined a group of proteinase inhibitors of 
the peptidyl fluoromethane, diazomethane, and pep- 
tidylmethyl sulfonium salt classes for a possible effect 
on the intraerythrocytic development of the human 
malarial parasite, Plasmodium falciparum, with the 
results described below. 
2. MATERIALS AND METHODS 
Cultures of human A+ erythrocytes at a haematocrit of 5% in a 
standard culture system [21] were infected with P. fufcipurum strain 
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Table 1 
Source Concentration producing 50% 
inhibition of growth (nM) 
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Fig.1. Effect of Cbz-Phe-ImNva-CHzF on the morphology of intraerythrocytic P. fulciparum. A, control culture; B, culture after treatment 
with 40 nM of the inhibitor for 4 h. An enlarged food vacuole in the trophozoite is arrowed. 
NF54. Parasites were synchronized using 5% sorbitol [22] and 
cultured for an additional one or two cycles. When parasites reached 
the ring stage, culture volumes were adjusted to a parasitaemia of 
0.5-l% at a haematocrit of 5%, then incubated with proteinase in- 
hibitors at 37°C in an atmosphere of 5% COzfS% Oz/90% Nz. After 
24 h, tritiated h~oxanthine (4,&/ml) was added to the cultures and 
after an additional 24 h, erythrocytes were harvested and incorpora- 
tion of radioactivity was determined and used as an estimate of the 
rate of parasite multiplication [23]. 
3. RESULTS AND DISCUSSION 
Nine synthetic proteinase inhibitors were examined, 
chiefly peptidyl fluoromethanes, but two other types 
were also included, a diazomethane and a pair of 
sulfonium salts. In the Pi position [24] both neutral and 
positively charged amino acids were included since the 
specificity of proteolysis is often directed to this 
residue. Two of the inhibitors were pa~icul~ly effec- 
tive in inhibiting development of intraerythrocytic P. 
falciparum (the first two in table 1). The concentrations 
required to produce 50% inhibition of parasite division 
were similar to those of chloroquine, a widely used an- 
timalarial drug (which for this strain has an 1% of 1.28 
x 1o-8 M). 
Morphology changes accompanying the inhibition of 
intraerythrocytic development of P. falciparum includ- 
ed enlargement of food vacuoles within the parasite 
(fig. 1). It may be that the proteinase inhibitors produce 
these effects by inhibiting digestive proteinases within 
parasite food vacuoles. Independent observations made 
with one of the less effective inhibitors of the present 
study, Cbz-Phe-AlaCHzF, led to a similar interpreta- 
tion of its action [5]. However, in that study it was con- 
cluded that the proteinase affected may be cathepsin-L 
like. In fact, such a possibility would suggest a lack of 
selective toxicity. 
An important characteristic of affinity labelling 
reagents uch as those in table 1 is the influence of pep- 
tide sequence. With an unknown proteinase, the varia- 
tion in susceptibility to inhibitors of different sequences 
provides information about the specificity of the pro- 
teinase, analogous to examining a group of synthetic 
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substrates. The results in table 1 suggest that the most 
susceptible plasmodial proteinase is not cathepsin L- 
like, although they may belong to the same gene family, 
since cathepsin L is 10 times more susceptible to an in- 
hibitor containing the Cbz-Phe-Ala- sequence than one 
with Cbz-Leu-Tyr- 1181, whereas in table 1 the 
fluoromethane with the latter sequence is more than 50 
times more effective, indicating quite a different bin- 
ding site. This is promising with respect to developing 
inhibitors selective for an important plasmodial pro- 
teinase but without action on host cell function, thereby 
permitting treatment of human malarial infections in 
vivo. While it is not yet certain that the inhibition we 
describe is due to inactivation of a proteinase, it is very 
likely, since the fluoromethane group is unreactive and 
forms covalent bonds largely as a result of complex for- 
mation with a target enzyme [S]. The use of such 
reagents in radioactive form should permit the iden- 
tification of the inactivated protease and characteriza- 
tion of its specificity in the usual manner. 
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